There’s a story most people are still being told about weight loss medication: take it, lose the weight, come off it, keep the result. It sounds reasonable. It’s also wrong, and the gap between that story and what the evidence actually shows is one of the most important things to understand before starting a clinical weight management program.
The claim
Weight loss medication is a temporary tool. You use it to kickstart weight loss, build new habits while it’s working, and come off it once you’ve reached your target. The weight stays off because the habits stay.
Where it comes from
Partly from how we’ve always talked about weight: as a willpower problem with a finish line. Partly from older weight-loss drugs, which were genuinely short-term. And partly from how the new generation of medications was first marketed to consumers, before clinicians and regulators caught up with the language.
What the evidence actually says
Across multiple high-quality randomised trials, the same pattern shows up: when GLP-1-based weight loss medication is stopped, weight returns. The STEP 4 and SURMOUNT 4 withdrawal trials, the most rigorous studies of what happens after discontinuation, both show rapid weight regain, typically within a year, alongside a decline in cardiometabolic benefits. In the original GLP-1 medication extension trial, participants regained roughly two-thirds of the weight they had lost within twelve months of stopping.
This isn’t a failure of the medication, and it isn’t a failure of the person taking it. It’s how the underlying biology works. Body weight is defended by the brain: by appetite regulation, by metabolic rate, by hunger and satiety hormones. Weight loss medication works by changing those signals. When the medication stops, that effect is lost, and the metabolic adaptations that occurred during weight loss (increased hunger, reduced resting metabolic rate, lower total energy expenditure) push weight back up.
The way this is now being framed in obesity medicine is worth paying attention to. Researchers and clinicians are moving away from the word “rebound.” The term implies individual failure, when what’s actually happening is predictable disease biology. A more accurate description is disease recurrence: consistent with obesity as a chronic, relapsing condition. The same way blood pressure rises when antihypertensives are stopped, or asthma symptoms return when inhaled steroids stop. No one calls that a rebound. It’s the disease, doing what the disease does.
The international guidance is now explicit about this. In December 2025, the World Health Organization released its first global guideline on GLP-1 medications for obesity, framing obesity as a chronic, relapsing disease and recommending long-term, continuous use when clinically appropriate.
What a better version of the claim would look like
The version that’s actually supported by the evidence: weight loss medication is a long-term treatment for a long-term condition. Some people will stay on it for years. Some will step down to a lower maintenance dose. Some will come off it under clinical supervision and accept that weight will partially return, and that’s a legitimate decision, made with eyes open, not a failed attempt at a cure.
This reframe changes the practical questions worth asking. Not how fast can I lose weight, but am I ready for a long relationship with this treatment? Not what’s my goal weight, but what does success look like for me beyond a number on a scale? As Toronto obesity medicine physician Dr Sasha High has argued, the deeper work in any weight loss journey isn’t the meal plan or the macros: it’s how you think about your body and your relationship with food. That work doesn’t end when the weight does.
Obesity is a chronic disease. The medication is part of the long arc of managing it. And the most important thing to know before you start is what success actually looks like, not a finish line, but a treatment that keeps working as long as you keep treating.